How strong is the evidence that immunotherapy in children prevents the progression of allergy and asthma?

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 6, 2007, Pages 556-560

  Jacobsen, Lars ^a   Valovirta, Erkka ^b  

^a Allergy Learning and Consulting   (Denmark)

^b Turku Allergy Center   (Finland)

Author keywords

Allergy; Asthma; Immunotherapy; Prevention; Rhinitis

Indexed keywords

HISTAMINE; IMMUNOMODULATING AGENT;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; BRONCHUS HYPERREACTIVITY; CHILD HEALTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DERMATOPHAGOIDES; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE COURSE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; NONHUMAN; PATHOPHYSIOLOGY; PRICK TEST; PRIORITY JOURNAL; PROGNOSIS; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOCONJUNCTIVITIS; RISK FACTOR; SECONDARY PREVENTION; SKIN SENSITIZATION;

ASTHMA; HUMANS; IMMUNOGLOBULIN E; IMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, SEASONAL;

EID: 35948961544     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3282f1d67e     Document Type: Review

References (48)

1. Togias A. Mechanisms of nose-lung interaction. Allergy 1999; 54 (Suppl 57):94-105.
2. Simons FE. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1999; 104:534-540.
3. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive summary of the workshop report. 7-10 December 1999, Geneva, Switzerland. Allergy 2002; 57:841-855.
4. Jacobsen L, Chivato T, Andersen P, et al. The co-morbidity of allergic hay fever and asthma in randomly selected patients with respiratory allergic diseases. Allergy 2002; 57 (Suppl 73):23.
5. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000; 106 (5 Suppl):S201-S205.
6. Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002; 109:419-425.
7. Linneberg A, Henrik NN, Frolund L, et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy 2002; 57:1048-1052.
8. Rackemann FM, Edwards RN. Asthma in children. A follow-up study of 688 patients after an interval of twenty years. N Engl J Med 1952; 246:815-823.
9. Linna O, Kokkonen J, Lukin M. A 10-year prognosis for childhood allergic rhinitis. Acta Paediatr 1992; 81:100-102.
10. Pedersen PA, Weeke ER. Asthma and allergic rhinitis in the same patients. Allergy 1983; 38:25-29.
11. Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994; 15:21-25.
12. Townley RG, Ryo UY, Kolotkin BM, Kang B. Bronchial sensitivity to methacholine in current and former asthmatic and allergic rhinitis patients and control subjects. J Allergy Clin Immunol 1975; 56:429-442.
13. Ramsdale EH, Morris MM, Roberts RS, Hargreave FE. Asymptomatic bronchial hyperresponsiveness in rhinitis. J Allergy Clin Immunol 1985; 75:573-577.
14. Madonini E, Briatico Vangosa G, Pappacoda A, et al. Seasonal increase of bronchial reactivity in allergic rhinitis. J Allergy Clin Immunol 1987; 79:358-363.
15. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-256.
16. Ciprandi G, Buscaglia S, Pesce G, et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 1995; 96:971-979.
17. Braunstahl GJ, Prins JB, Kleinjan A, et al. Nose and lung cross-talk in allergic airways disease. Clin Exp Allergy Rev 2003; 3:38-42.
18. Jacobsen L. Preventive aspects of immunotherapy: prevention for children at risk of developing asthma. Ann Allergy Asthma Immunol 2001; 87 (1 Suppl 1):43-46.
19. Silvestri M, Rossi GA, Cozzani S, et al. Age-dependent tendency to become sensitized to other classes of aeroallergens in atopic asthmatic children. Ann Allergy Asthma Immunol 1999; 83:335-340.
20. Linneberg A, Nielsen NH, Madsen F, et al. Pets in the home and the development of pet allergy in adulthood. The Copenhagen Allergy Study. Allergy 2003; 58:21-26.
21. Malling HJ, Weeke B. Immunotherapy. Position Paper of the European Academy of Allergology and Clinical Immunology. Allergy 1993; 48 (Suppl 14): 9-35.
22. Bousquet J, Lockey RF, Malling HJ. Allergen Immunotherapy: therapeutic vaccines for allergic diseases. WHO Position Paper. Allergy 1998; 53 (Suppl 44):1-42.
23. Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007; 119:881-891.
24. Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988; 82:470-480.
25. Walker SM, Varney VA, Gaga M, et al. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995; 50:405-413.
26. Hamid QA, Schotman E, Jacobson MR, et al. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997; 99:254-260.
27. Ebner C, Siemann U, Bohle B, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27:1007-1015.
28. Wilson DR, Nouri-Aria KT, Walker SM, et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001; 107:971-976.
29. Wachholz PA, Nouri-Aria KT, Wilson DR, et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 2002; 105:56-62.
30. Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children - a 14-year study. Pediatrics 1968; 42:793-802.
31. Bauer CP. Untersuchung zur Asthmaprävention durch die specifische Immuntherapie bei Kindern [Study of preventing the development of asthma during specific immunotherapy in children]. Allergologie 1993; 11:468.
32. Grembiale RD, Camporota L, Naty S, et al. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000; 162:2048-2052.
33. Jacobsen L, Nuchel PB, Wihl JA, et al. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997; 52:914-920.
34. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114:851-857.
35. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999; 318:593-596.
36. Johnstone DE, Crump L. Value of hyposensitization therapy for perennial bronchial asthma in children. Pediatrics 1961; 61:39-44.
37. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99:450-453.
38. Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-1397.
39. Purello-D'Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001; 31:1295-1302.
40. Marogna M, Spadolini I, Massolo A, et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 2004; 59:1205-1210.
41. Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006; 61:855-859. Five-year results for the PAT study, which is the cornerstone of scientific evidence of the preventive capacity of allergen SIT.
42. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943-948. The 10-year results from the PAT study confirm the results from the 5-year PAT study in the prevention of asthma and show that the clinical effect persisted at the 10-year follow-up.
43. Woodcock A, Lowe LA, Murray CS, et al. Early life environmental control - effect on symptoms, sensitization, and lung function at age 3 years. Am J Respir Crit Care Med 2004; 170:433-439.
44. Cullinan P, MacNeill SJ, Harris JM, et al. Early allergen exposure, skin prick responses, and atopic wheeze at age 5 in English children: a cohort study. Thorax 2004; 59:855-861.
45. Burr M, Emberlin JC, Treu R, et al. ISAAC Phase One Study Group. Pollen counts in relation to the prevalence of allergic rhinoconjunctivitis, asthma and atopic eczema in the International Study of Asthma and Allergies in Childhood (ISAAC). Clin Exp Allergy 2003; 33:1675-1680.
46. ETAC Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomized, placebo-controlled trial: first results of ETAC. Early Treatment of the Atopic Child. Pediatr Allergy Immunol 1998; 9:116-124.
47. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354:1985-1997. An important study of inhaled corticosteroids in childhood asthma showing no preventive potential after cessation of treatment.
48. Bisgaard H, Hermansen MN, Loland L, et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006; 354:1998-2005.